Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication

References

• Calvet X, Ramírez Lázaro MJ, Lehours P, et al. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter. 2013;18:5–11.
   PubMed Web of Science ®Google Scholar
• Arslan N, Yilmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017;23(16):2854–2869.
   PubMed Web of Science ®Google Scholar
• Bastos J, Peleteiro B, Barros R, et al. Sociodemographic determinants of prevalence and incidence of Helicobacter pylori infection in portuguese adults. Helicobacter. 2013;18(6):413–422.
   PubMed Web of Science ®Google Scholar
• Oleastro M, Pelerito A, Nogueira P, et al. Prevalence and incidence of Helicobacter pylori infection in a healthy pediatric population in the lisbon area. Helicobacter. 2011;16(5):363–372.
   PubMed Web of Science ®Google Scholar
• Bastos J, Peleteiro B, Pinto H, et al. Prevalence, incidence and risk factors for Helicobacter pylori infection in a cohort of portuguese adolescents (EpiTeen). Dig Liver Dis. 2013;45(4):290–295.
   PubMedGoogle Scholar
• Almeida N, Romãozinho JM, Donato MM, et al. Helicobacter pylori antimicrobial resistance rates in the Central region of Portugal. Clin Microbiol Infect. 2014;20(11):1127–1133.
   PubMed Web of Science ®Google Scholar
• McColl KEL. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–1604.
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–789.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4(1):5–19.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768–775.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, et al. Management of helicobacter pylori infection-the maastricht V/florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Venerito M, Link A, Rokkas T, et al. Gastric cancer – clinical and epidemiological aspects. Helicobacter. 2016;21:39–44.
   PubMed Web of Science ®Google Scholar
• Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol. 2014;20(19):5660–5665.
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BCY, Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–1825.
   PubMed Web of Science ®Google Scholar
• Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: a review of current trends. Niger Med J. 2013;54(1):1–4.
   PubMedGoogle Scholar
• De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59(4):783–785.
   PubMed Web of Science ®Google Scholar
• Almeida N, Donato MM, Romãozinho JM, et al. Beyond maastricht IV: are standard empiric triple therapies for helicobacter pylori still seful in a South-European country? BMC Gastroenterol. 2015;15:23.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier J-C, et al. Éradication de Helicobacter pylori avec une gélule contenant du sous-citrate de bismuth, du métronidazole et de la tétracycline donnée avec oméprazole versus trithérapie à base de clarithromycine: essai phase 3 randomisé ouvert de non infériorité. Cancéro Dig. 2011;3:137–139.
   Google Scholar
• Malfertheiner P. Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7(10):538–539.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628–638.
   PubMed Web of Science ®Google Scholar
• van Zanten SV, Farley A, Marcon N, et al. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study. Can J Gastroenterol. 2000;14(7):599–602.
   PubMed Web of Science ®Google Scholar
• Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to East London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 1994;35(11):1562–1566.
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Giorgetti G, et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. Panminerva Med. 2014;56:57–61.
   PubMed Web of Science ®Google Scholar
• Lopo I, Libânio D, Pita I, et al. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis. Helicobacter. 2018;23(4):e12493.
   PubMed Web of Science ®Google Scholar
• Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802–807.e1.
   PubMed Web of Science ®Google Scholar
• Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40(2):171–177.
   PubMed Web of Science ®Google Scholar
• De Boer WA, Van Etten RJXM, Lai JYL, et al. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter. 1996;1(3):145–150.
   PubMedGoogle Scholar
• Tursi A, Elisei W, Giorgetti ÞG, et al. Efficacy, tolerability, and factors affecting the efficacy of the sequential therapy in curing Helicobacter pylori infection in clinical setting. J Investig Med. 2011;59(6):917–920.
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98(3):562–567.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905–913.
   PubMed Web of Science ®Google Scholar